Scenic Biotech

Meet with our Senior Director of Finance & Corporate Development, Frederik Gorter de Vries, and Scenic’s Business Development & Alliance Manager, Charlotte Blessing, PhD, at next week’s #BIOEurope Fall on November 4-6. Schedule a 1:1 meeting with Frederik and Charlotte to learn more about our lead program targeting Niemann Pick Type C and how we are currently advancing the first-in-class drug toward clinical evaluation. To schedule a meeting with Scenic via the partnering program at: https://bit.ly/4812PIP

Meet with our Senior Director of Finance & Corporate Development, Frederik Gorter de Vries, and Scenic’s Business Development & Alliance Manager, Charlotte Blessing, PhD, at next week’s #BIOEurope Fall on November 4-6. Schedule a 1:1 meeting with Frederik and Charlotte to learn more about our lead program targeting Niemann Pick Type C and how we are currently advancing the first-in-class drug toward clinical evaluation. To schedule a meeting with Scenic via the partnering program at: https://bit.ly/4812PIP

Connect with Scenic’s Business Development & Alliance Manager, Charlotte Blessing, PhD, at the World Orphan Drug Congress Europe in Barcelona, October 22-25. Join Charlotte at the largest, most established European meeting dedicated to orphan drugs and ask about our robust pipeline of disease-modifying therapies with strong genetic links to disease.

Don’t miss the opportunity to meet with Scenic’s Head of Business Development, Sebastian Franzinger, at next week’s #BIO Investor Forum on October 15-16 in San Francisco! We look forward to meeting with industry leaders and investors to discuss how we are using our proprietary platform technology to generate disease-modifying therapeutics for a range of indications.

Don’t miss the chance to join our Director of Translational Research, Philipp Alberts (Ph.D), at the Awesome Lysosome Meeting hosted by Tigem    Philipp will be among the world’s leading experts in lysosomal research to speak on Scenic Biotech’s discovery of a novel Niemann Pick type C (NPC) disease modifier and its development towards the clinic.   To learn more about our genetic modifier approach and our pipeline of disease-modifying therapies targeting neuro- and metabolic diseases with high unmet medical need, visit https://lnkd.in/duED2paE

Meet us in Boston! Our CEO, Oscar Izeboud, will give a presentation tomorrow entitled “Modifier therapy: a new approach to target neuro- and metabolic disease” at 12:15 pm EST during the Biotech showcase at LSX World Congress USA. We are eager to connect for 2 days with the key players driving the future of healthcare and see the latest innovations in the field. If you are also attending and want to learn more about Scenic’s radically new approach to treating genetic disorders, reach out via the partneringONE platform!   #LSXUSA #HealthcareInnovation #LifeSciences

At Scenic, we are committed to transforming the treatment of genetic disorders through our pioneering modifier therapy. We believe in the power of connecting with communities affected by orphan and rare diseases, which is why Vincent Blomen, will be attending the Barth Syndrome Foundation (BSF) Biennial International Scientific, Medical, and Family Conference to discuss a novel therapeutic target for Barth Syndrome during the Poster Session on August 1, 2024

Today, we have announced the appointment of Ben Machielse to Scenic’s Board of Directors. Ben brings over 25 years of drug development expertise, covering all stages from preclinical evaluation to commercialization, from life science companies, including Sucampo Pharmaceuticals-acquired Vtesse and AstraZeneca-acquired Omthera Pharmaceuticals. We welcome Ben to our board and look forward to having his drug development expertise for rare diseases as we accelerate our pipeline of innovative modifier therapies toward the clinic. Read the full press release to find out more about this announcement: https://lnkd.in/dN8WZt6a

Today, we have announced the appointment of Ben Machielse to Scenic’s Board of Directors. Ben brings over 25 years of drug development expertise, covering all stages from preclinical evaluation to commercialization, from life science companies, including Sucampo Pharmaceuticals-acquired Vtesse and AstraZeneca-acquired Omthera Pharmaceuticals. We welcome Ben to our board and look forward to having his drug development expertise for rare diseases as we accelerate our pipeline of innovative modifier therapies toward the clinic. Read the full press release to find out more about this announcement: https://lnkd.in/dN8WZt6a

Our Head of Translational Research, Guido Hartmann will be leading a presentation entitled “Discovery of a novel NPC disease modifier and development towards its clinical application” at next week's NATIONAL NIEMANN-PICK DISEASE FOUNDATION Family Support & Medical Conference (NNPDF) on July 12 at 11:45 am MDT in Salt Lake City. The NNPDF conference is a unique opportunity to connect with expert clinicians, researchers, and families affected by Niemann-Pick disease.   Join us to learn about the latest advances in evolution-inspired medicine and how Scenic Biotech is pioneering modifier therapy to treat genetic disorders, including Niemann-Pick disease.   Together, as one voice, we can achieve urgently needed clinical treatments and support ongoing research towards a cure.   We look forward to seeing you there!   #NNPDF2024 #ModifierTherapy #NiemannPickDisease